US EditionPublished • loading... • Updated
Roche Sales Down 5% as Currency Effects Outweigh Gains for Haemophilia Drug
The drugmaker said sales rose 6% at constant exchange rates, offsetting weaker reported results and keeping its full-year guidance unchanged.
- Roche reported first-quarter sales of CHF 14.7 billion , down 5% in Swiss currency but up 6% at constant exchange rates, as the appreciating franc dampened reported results.
- The Swiss currency's appreciation as a safe-haven asset amid geopolitical unrest drove the decline, while underlying business strength remained consistent with the company's annual guidance targets.
- Key growth drivers included multiple sclerosis drug Ocrevus, which grew 6% to CHF 1.69 billion, Hemlibra rising 13% to CHF 1.19 billion, and Vabysmo increasing 13% to CHF 1.02 billion.
- CEO Thomas Schinecker defended the results, noting sales in dollars increased 9%, and highlighted Roche's $50 billion capital investment program in the U.S. to mitigate tariff risks.
- Schinecker anticipates launching up to 19 new medicines by 2030 and aims to capture double-digit market share in weight-loss with experimental drug CT-388 alongside Novo Nordisk and Eli Lilly.
Insights by Ground AI
12 Articles
12 Articles
Coverage Details
Total News Sources12
Leaning Left2Leaning Right0Center3Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
L 40%
C 60%
Factuality
To view factuality data please Upgrade to Premium
